BCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameBCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics)
Drug Alias NameBCMA-CS1 cCAR T cells (iCell Gene Therapeutics)lentiviral transfected chimeric antigen receptor T-cells therapy(iCell Gene Therapeutics)lentiviral transfected chimeric antigen receptor T-cells modified to target B-cell maturation antigen and CS1(iCell Gene Therapeutics)
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-cell maturation protein modulatorsSLAM family member 7 modulators
TargetsSLAM family member 7B-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesIcell Gene Therapeutics (Int'L) Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesiCell Gene Therapeutics LLCiCar Bio Therapeutics Ltd
Active IndicationsN/A
Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A
Related LinksN/A